Paper34406366
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
Eichenfield LF and 14 others. JAMA Dermatol, 2021. Cited by 139 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. Papers, record 34406366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34406366
- Disease
- atopic eczema238 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dermatitis, Atopic | Major topic |
| Eczema | Major topic |
| Adolescent | |
| Child | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Pyrimidines | |
| Severity of Illness Index | |
| Sulfonamides | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03796676 | JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 34668957 | Errors in Table 1, Figure 3, and Results. | https://conductscience.org/library/papers/34668957 |
Source PubMed
Cited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 139 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42844558 | Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/42844558 | PubMed |
| 42789457 | Update on biologic and small molecules treatments in pediatric allergic diseases. | Pediatr Allergy Immunol | 2026 | https://conductscience.org/library/papers/42789457 | PubMed |
| 42667571 | Real-World Use of Abrocitinib for Moderate-to-Severe Atopic Dermatitis in the United States Based on Electronic Health Records and Administrative Claims. | Adv Ther | 2026 | https://conductscience.org/library/papers/42667571 | PubMed |
| 42630413 | A systemic epithelial-immune-neural framework for pediatric atopic dermatitis-allergic rhinitis comorbidity. | Front Immunol | 2026 | https://conductscience.org/library/papers/42630413 | PubMed |
| 42577450 | Efficacy and safety of the JAK1 inhibitor abrocitinib for moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42577450 | PubMed |
| 42415197 | The JAK-STAT pathway in allergic diseases: from pathogenesis to targeted therapy. | Biomark Res | 2026 | https://conductscience.org/library/papers/42415197 | PubMed |
| 42356139 | Dose Adjustment of JAK Inhibitors for the Management of Moderate-to-Severe Atopic Dermatitis: A Single-Centre Retrospective Study. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42356139 | PubMed |
| 42328000 | Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation. | Allergol Select | 2026 | https://conductscience.org/library/papers/42328000 | PubMed |
| 42220541 | Real-world effectiveness and safety of 200 mg abrocitinib initiation in Chinese adults with moderate-to-severe atopic dermatitis: a retrospective study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42220541 | PubMed |
| 42187316 | Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients. | J Eur Acad Dermatol Venereol | 2026 | https://conductscience.org/library/papers/42187316 | PubMed |
| 42162528 | Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/42162528 | PubMed |
| 42148141 | Comparative efficacy of pediatric atopic dermatitis treatments: a network meta-analysis highlighting dupilumab and pimecrolimus for SCORAD and EASI improvement. | Front Immunol | 2026 | https://conductscience.org/library/papers/42148141 | PubMed |
| 42047411 | Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years. | J Eur Acad Dermatol Venereol | 2026 | https://conductscience.org/library/papers/42047411 | PubMed |
| 42018850 | Use of abrocitinib in severe atopic dermatitis. | Rev Assoc Med Bras (1992) | 2026 | https://conductscience.org/library/papers/42018850 | PubMed |
| 42008061 | Treatment Patterns and Perceptions of Treatment Options in Japanese Pediatric and Adolescent Patients with Atopic Dermatitis. | Adv Ther | 2026 | https://conductscience.org/library/papers/42008061 | PubMed |
| 41897097 | Real-World Treatment Patterns and Determinants of Therapy in Pediatric Atopic Dermatitis: A 10-Year Experience from a Tertiary Referral Center in Thailand. | Children (Basel) | 2026 | https://conductscience.org/library/papers/41897097 | PubMed |
| 41670770 | Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD Registry. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/41670770 | PubMed |
| 41413320 | Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/41413320 | PubMed |
| 41405747 | Pathophysiologic Mechanisms and Targeted Treatments Associated with the Nervous System in Cutaneous Allergic Diseases. | Clin Rev Allergy Immunol | 2025 | https://conductscience.org/library/papers/41405747 | PubMed |
| 41403263 | Efficacy and Safety of Abrocitinib in an Elderly Chinese Population with Moderate-to-Severe Atopic Dermatitis: A Non-randomized Controlled Trial. | Acta Derm Venereol | 2025 | https://conductscience.org/library/papers/41403263 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| LOC102723407 | 102723407 | PubTator's text mining | https://conductscience.org/library/genes/102723407 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ABROCITINIB | CHEMBL3655081 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3655081 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34406366
GET https://conductscience.org/api/papers/v1/34406366/cited_by?page=2